# Glossary Terms

**Anemia (iron deficiency anemia):** A condition that develops when the body lacks sufficient red blood cells. Symptoms of anemia may include fatigue, weakness, and shortness of breath, among others.

**Genetic Testing (molecular profiling or biomarker testing):** Laboratory testing that identifies certain gene mutations, proteins, chromosomal abnormalities and/or other molecular changes that are unique to an individual’s disease. In cancer, it may be used to evaluate treatment or to make a prognosis.

**JAK2 (JAK2V617F) Mutation:** An acquired mutation in the majority of patients with myeloproliferative neoplasms. The mutation is found in approximately 50% of myelofibrosis (MF) and essential thrombocythemia (ET) patients and 95% of polycythemia vera (PV) patients.

**Splenomegaly:** Enlarged spleen.

**Stem Cell Transplant (bone marrow transplant):** Procedure in which healthy blood stem cells are used to replace damaged or diseased bone marrow. This procedure can be used to treat certain types of blood cancers.

**Tissue Bank:** An organization that collects, stores, and distributes human biological specimens for research purposes.

## Therapies Being Studied to Treat Myelofibrosis

<table>
<thead>
<tr>
<th>Pelabresib (BET inhibitor)</th>
<th>JAK Inhibitors: A class of therapy that interferes with the activation of the JAK-STAT pathway.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Navitoclax (BCLXL-BCL2 inhibitor)</td>
<td>Approved JAK Inhibitors for Myelofibrosis:</td>
</tr>
<tr>
<td>Selinexor (Xpovio)</td>
<td>- Ruxolitinib (Jakafi)</td>
</tr>
<tr>
<td>Navtemadlin (MDM2 inhibitor)</td>
<td>- Pacritinib (Vonjo)</td>
</tr>
<tr>
<td>PIM1 kinase inhibitor (TP-3654)</td>
<td>- Fedratinib (Inrebic)</td>
</tr>
<tr>
<td>Lysyl oxidase (LOX) inhibitor</td>
<td>- Momelotinib (Ojjaara)</td>
</tr>
<tr>
<td>LSD1 inhibitor</td>
<td></td>
</tr>
</tbody>
</table>

## Questions to Ask About Clinical Trials

- What medicine will I receive?
- Is there a placebo?
- What group will I be assigned to?
- What phase is the study?
- What is the time commitment?
- Are there any financial reimbursements?

## Educational Resources

- [LLS | Clinical Trials](#)
- [PEN | Office Visit Planners](#)

**Thank You**

Cancer Support Community

CancerGRACE

CURE

The Leukemia & Lymphoma Society (LLS)

Evolve Myelofibrosis is brought to you by the Patient Empowerment Network. Funding is provided by a sponsorship from Merck, MorphoSys, and through generous donations from people like you.